Lomond Therapeutics Holdings, Inc.
Clinical trials sponsored by Lomond Therapeutics Holdings, Inc., explained in plain language.
-
New hope for tough blood cancers: first patients test experimental drug
Disease control Recruiting nowThis is the first study in people testing a new drug called ZE50-0134 for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to other treatments. The main goals are to find a safe dose and see how the body h…
Phase: PHASE1 • Sponsor: Lomond Therapeutics Holdings, Inc. • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC
-
New hope for leukemia patients who have run out of options
Disease control Recruiting nowThis is a first-in-human study to test a new drug, ZE46-0134, for adults with a hard-to-treat blood cancer called acute myeloid leukemia (AML). The cancer has come back or resisted standard treatment and has specific genetic changes (FLT3 or spliceosome mutations). The main goals…
Phase: PHASE1 • Sponsor: Lomond Therapeutics Holdings, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC